Phase I-II trial of twice-weekly gemcitabine and concomitant irradiation in patients undergoing pancreaticoduodenectomy with extended lymphadenectomy for locally advanced pancreatic cancer

International Journal of Radiation Oncology Biology Physics

Volumn 60, Issue 2, 2004, Pages 444-452

  Joensuu, Timo K ^a   Kiviluoto, Tuula ^a   Kärkkäinen, Päivi ^a   Vento, Pälvi ^a   Kivisaari, Leena ^a   Tenhunen, Mikko ^a   Westberg, Ronny ^b   Elomaa, Inkeri ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b RW Clinical Research   (Sweden)

Author keywords

Gemcitabine; Neoadjuvant chemoradiotherapy; Pancreatic cancer; Radical surgery

Indexed keywords

DISEASE CONTROL; DISEASES; DRUG INFUSION; PATIENT MONITORING; RADIOTHERAPY; SURGERY; TOXICITY; TUMORS;

CONCOMITANT IRRADIATION; INFECTION; MAXIMUM TOLERATED DOSE (MTD); PANCREATIC CANCER;

DOSIMETRY;

GEMCITABINE;

ADULT; AGED; ANEMIA; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; DYSPEPSIA; EDEMA; FATIGUE; FEMALE; FEVER; HUMAN; INFECTION; LEUKOPENIA; LIVER TOXICITY; LYMPHADENECTOMY; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PANCREAS CANCER; PANCREATICODUODENECTOMY; PRIORITY JOURNAL; RADIATION DOSE; SKIN TOXICITY; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, PANCREATIC DUCTAL; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; FEMALE; HUMANS; LYMPH NODE EXCISION; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOADJUVANT THERAPY; PANCREATECTOMY; PANCREATIC NEOPLASMS; PANCREATICODUODENECTOMY; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY DOSAGE;

EID: 4544322346     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2004.03.026     Document Type: Article

References (46)

1. Finnish cancer registry 2000. www.cancerregistry.fi/eng/statistics.htm. Accessed March 4, 2004
2. Anonymous. 2003. www.cdc.gov/cancer/npcr/uscs/2000/cancer_incidence.htm. Accessed July 11, 2003
3. Roder J.D., Stein H.J., Hüttl W., et al. Pylorus-preserving versus standard pancreaticoduodenectomy an analysis of 110 pancreatic and periampullary carcinomas. Br J Surg. 79:1992;152-155
4. Nitecki S.S., Sarr M.G., Colby T.V., et al. Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is It Really Improving? Ann Surg. 221:1995;59-66
5. Tsao J.I., Rossi R.R., Lowell J.A. Pylorus preserving pancreatoduodenectomy. Is it an adequate cancer operation? Arch Surg. 129:1994;405-412
6. Willett C.G., Lewandrowski K., Warshaw A.L., et al. Resection margins in carcinoma of the head of the pancreas. Implications for radiation therapy. Ann Surg. 217:1993;144-148
7. Allema J.H., Reinders M.E., van Gulik T.M., et al. Prognostic factors for survival after pancreaticoduodenectomy for patients with carcinoma of the pancreatic head region. Cancer. 75:1995;2069-2076
8. Geer R.J., Brennan M.F. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg. 165:1993;68-73
9. Cameron J.L., Crist D.W., Sitzmann J.V., et al. Factors influencing survival after pancreaticoduodenectomy for pancreatic cancer. Am J Surg. 161:1991;120-125
10. Trede M., Schwall G., Saeger H.-D. Survival after pancreaticoduodenectomy. 118 consecutive resections without an operative mortality. Ann Surg. 211:1990;447-458
11. Warshaw A.L., Fernández C. Pancreatic carcinoma. N Engl J Med. 326:1992;455-465
12. Burris H.A. III, Moore M.J., Andersen J., et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer A randomized trial. J Clin Oncol. 15:1997;2403-2413
13. Rothenberg M.L., Moore M.J., Cripps M.C., et al. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol. 7:1996;347-353
14. Shewach D.S., Hahn T.M., Chang E., et al. Metabolism of 2′,2′-difluoro-2′-deoxycytidine and radiation sensitization of human colon carcinoma cells. Cancer Res. 54:1994;3218-3223
15. Lawrence T.S., Chang E.Y., Hahn T.M., et al. Delayed radiosensitization of human colon carcinoma cells after a brief exposure to 2′,2′- difluoro-2′-deoxycytidine (gemcitabine). Clin Cancer Res. 3:1997;777-782
16. Greene FL, Page DL, Fleming ID, et al., editors. AJCC cancer staging handbook. New York: Springer; 2002
17. International Commission on Radiation Units and Measurements. ICRU Report 50. Prescribing, recording and reporting photon beam therapy. 1993;ICRU, Bethesda, MD
18. Evans D.B., Rich T.A., Byrd D.R., et al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg. 127:1992;1335-1339
19. Pisters P.W., Abbruzzese J.L., Janjan N.A., et al. Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma. J Clin Oncol. 16:1998;3843-3850
20. McGinn C.J., Zalupski M.M., Shureiqi I., et al. Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol. 19:2001;4202-4208
21. Abrams R.A., Lillemoe K.D., Piantadosi S. Continuing controversy over adjuvant therapy of pancreatic cancer. Lancet. 358:2001;1565-1566
22. Crane C.H., Abbruzzese J.L., Evans D.B., et al. Is the therapeutic index better with gemcitabine- based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer? Int J Radiat Oncol Biol Phys. 52:2002;1293-1302
23. Blackstock A.W., Bernard S.A., Richards F., et al. Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer. J Clin Oncol. 17:1999;2208-2212
24. Dent S.F., Eisenhauer E.A. Phase I trial design Are new methodologies being put into practice? [Review] Ann Oncol. 7:1996;561-566
25. Seymour L., Eisenhauer E. A review of dose-limiting events in phase I trials Antimetabolites show unpredictable relationships between dose and toxicity. [Review] Cancer Chemother Pharmacol. 47:2001;2-10
26. Tannock I.F. Treatment of cancer with radiation and drugs. J Clin Oncol. 14:1996;3156-3174
27. Warshaw A.L., Swanson R.S. Pancreatic cancer in 1988. Possibilities and probabilities. [Review] Ann Surg. 208:1988;541-553
28. Hoffman J.P., Lipsitz S., Pisansky T., et al. Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas An Eastern Cooperative Oncology Group Study. J Clin Oncol. 16:1998;317-323
29. Friess H., Kleeff J., Kulli C., et al. The impact of different types of surgery in pancreatic cancer. [Review] Eur J Surg Oncol. 25:1999;124-131
30. Park D.I., Lee J.K., Kim J.E., et al. The analysis of resectability and survival in pancreatic cancer patients with vascular invasion. J Clin Gastroenterol. 32:2001;231-234
31. Yeo C.J., Abrams R.A., Grochow L.B., et al. Pancreaticoduodenectomy for pancreatic adenocarcinoma Postoperative adjuvant chemoradiation improves survival. Ann Surg. 225:1997;621-636
32. Gastrointestinal Tumor Study Group. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer. 59:1987;2006-2010
33. Klinkenbijl J.H., Jeekel J., Sahmoud T., et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region. Phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg. 230:1999;776-784
34. Chakravarthy A., Abrams R.A., Yeo C.J., et al. Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma Acceptable toxicity and suggestion of improved 1-year disease-free survival. Int J Radiat Oncol Biol Phys. 48:2000;1089-1096
35. Demeure M., Doffek K., Komorowski R., et al. Molecular metastases in stage I pancreatic cancer Improved survival with adjuvant chemoradiation. Surgery. 124:1998;663-669
36. Spitz F.R., Abbruzzese J.L., Lee J.E., et al. Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol. 15:1997;928-937
37. Pendurthi T.K., Hoffman J.P., Ross E., et al. Preoperative versus postoperative chemoradiation for patients with resected pancreatic adenocarcinoma. Am Surg. 64:1998;686-692
38. Hoffman J.P., Weese J.L., Solin L., et al. A pilot study of preoperative chemoradiation for patients with localized adenocarcinoma of the pancreas. Am J Surg. 169:1995;71-78
39. Berlin J.D., Catalano P.J., Thomas J.P., et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma Eastern cooperative oncology group trial E2297. J Clin Oncol. 20:2002;3270-3275
40. Talamonti M.S., Catalano P.J., Vaughn D.J., et al. Eastern Cooperative Oncology Group phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer A regimen with unexpected early toxicity. J Clin Oncol. 18:2000;3384-3389
41. Brunner T.B., Grabenbauer G.G., Klein P., et al. Phase I trial of strictly time-scheduled gemcitabine and cisplatin with concurrent radiotherapy in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 55:2003;144-153
42. Lawrence TS. Radiosensitizing nucleosides. In: Perry MC, editor. American Society of Clinical Oncology. Educational book. Baltimore, MD, Lippincott Williams and Wilkins; 1999. p. 153-158
43. McGinn C.J., Shewach D.S., Lawrence T.S. Radiosensitizing nucleosides. JNCI Cancer Spectrum. 88:1996;1193-1203
44. Lawrence T.S., Chang E.Y., Hahn T.M., et al. Radiosensitization of pancreatic cancer cells by 2′2′-difluoro-2′-deoxicytidine. Int J Radiat Oncol Biol Phys. 34:1996;867-872
45. Rashleigh-Belcher H.J., Russell R.C., Lees W.R. Cutaneous seeding of pancreatic carcinoma by fine-needle aspiration biopsy. Br J Radiol. 59:1986;182-183
46. Rosewicz S., Wiedenmann B. Pancreatic carcinoma. Lancet. 349:1997;485-489